Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ELNEW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Bispecific nBT062-natalizumab-DM4
|
|||||
| Synonyms |
Bispecific nBT062 natalizumab DM4
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Multiple myeloma [ICD11:2A83]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Antibody Name |
Bispecific nBT062-natalizumab
|
Antibody Info | ||||
| Antigen Name |
Syndecan-1 (SDC1); Integrin alpha-4 (ITGA4)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Ravtansine
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 51.6
|
%
|
Breast cancer PDX model (PDX: MAXF 1322)
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
0.46
|
nM
|
NCI-H929 cells
|
Plasma cell myeloma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 51.60% (Day 56) | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
Bispecific nBT062-natalizumab-DM4 (4 mg/kg/week for three injections in total) induces efficient tumor cell killing in models of MAXF1322 mammary carcinoma cells with CD138 expression with high expression.
|
||||
| In Vivo Model | Breast cancer PDX model (PDX: MAXF 1322) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.46 nM | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 were added to the cells. Cells were incubated and after 5 days the viability was determined using the WST-1 cell proliferation assay.
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.